Results 241 to 250 of about 106,281 (309)

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy

Advanced Science, Volume 13, Issue 26, 8 May 2026.
A CD44‐targeted MnPt bimetallic nanozyme (HD@MnO2) integrates multienzyme‐like activity with cGAS–STING activation to boost radio‐immunotherapy. Through cascade biocatalysis, it depletes glutathione, relieves hypoxia, and amplifies ROS, enhancing radiotherapy‐induced DNA damage and immunogenic cell death. The nanozyme promotes dendritic cell maturation
Wenyi Zhang, Yangyang Guo, Guoping Xu, Luhaoxiang Liu, Lin Chen, Cai Zhang, Yiming Li, Jianmin Li, Yang Zhao   +8 more
wiley   +1 more source

Vanishing bile duct syndrome induced by Psoraleae Fructus: A case report and literature review. [PDF]

Medicine (Baltimore)
Liu M, Lei C, Tian HL, Wang QH, Dong XY.
europepmc   +1 more source

A Photothermal‐Responsive PRP‐Loaded Hydrogel Engineered With Composite Nanobottle for Controllable Delivery of Growth Factors and Multifunctional Therapy of Diabetic Wounds

Advanced Science, Volume 13, Issue 25, 4 May 2026.
A photothermal‐responsive engineered platelet‐rich plasma hydrogel (CNB‐ePRP) incorporated with thrombin‐functionalized composite nanobottle was developed, which enables in situ PRP activation, on‐demand growth factor release, multifunctionality, and personalized antimicrobial loading for treatment of diabetic wounds. The CNB‐ePRP hydrogel demonstrated
Wen‐Qiang Qu, Hui‐Yun Gu, Si‐Min Zeng, Chang‐Jiang Liu, Xiao Yan, Ting Pan, Chao Jian, Xian‐Zheng Zhang, Ai‐Xi Yu   +8 more
wiley   +1 more source

Severe hepatic lipidosis in a dog: a case report. [PDF]

Vet Res Forum
Abbasi F, Jafarbeglou A, Asri-Rezaei S, Mahmoudi SS, Davoodi F, Raisi A.   +5 more
europepmc   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1339-1351, May 2026.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Severe Hepatocellular Injury With Transaminases > 20,000 IU/L in Suspected Repeated Drug Ingestion Despite Undetectable Serum Levels. [PDF]

Cureus
Patel V, Khan RS, Rangasamy A, Shah R.
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review. [PDF]

Liver Int
van Eekhout KMA, Broekman LD, de Jong VD, Michel M, Grobbee R, Maya-Miles D, Romero-Gómez M, Muris J, Mendive JM, Vali Y, Franco OH, Schattenberg JM, Fournier-Poizat C, Castro Cabezas M, Tushuizen ME, Holleboom AG, GRIPonMASH consortium.   +16 more
europepmc   +1 more source

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Chinese Retrospective Multicenter Study Based on Global Meta‐Analysis

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective Microvascular invasion (MVI) has been identified as a risk factor for the prognosis of patients with hepatocellular carcinoma (HCC). However, it can only be diagnosed pathologically, and thus no widely applicable preoperative MVI risk prediction model has been established.
Jia Xu, Yue‐Lu Zhang, Man Yang, Zhengbo Deng, Laisheng Li, Ting Wang, Jinhua Song, Hai Xu, Jian Wu, Zhi‐Qi Wu, Hua‐Guo Xu   +10 more
wiley   +1 more source

Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review. [PDF]

Biochem Soc Trans
Alberti M, Miggiano R.
europepmc   +1 more source